There is no fixed stop date for valganciclovir maintenance after CMV retinitis in an HIV-negative patient. In this case a 29-year-old lymphoma patient needed induction, re-induction, repeated intravitreal injections, and 13 months of oral therapy before antiviral treatment could be stopped. Retinal inactivity and viral suppression drove the decision. No CD4+ T-cell threshold did.
Why the HIV playbook does not transfer
Most of what clinicians know about CMV retinitis comes from advanced HIV disease, and the stopping rules from that world are built for that world. HIV guidance lets maintenance therapy stop after at least three months of anti-CMV treatment, as long as the retinitis is inactive and the CD4+ count has held at or above 100 cells per microliter for at least three months on antiretroviral therapy.
None of that carries over. A patient on chemotherapy has no antiretroviral therapy to restart immune function, and CD4+ recovery after bendamustine is measured in years, not months. Borrow the HIV threshold and you stop treatment while the retinitis is still active.
The alternative framework was proposed for lymphoma-associated CMV retinitis and matches a recent Asia-Pacific consensus: keep treating until the ocular lesions are inactive, CMV viremia has resolved, and the underlying hematologic disease is stable. Three conditions, all of them at once. Valganciclovir maintenance is the bridge that carries the patient across the gap between viral suppression and immune recovery, and in this case that gap was roughly 13 months.
The immune damage bendamustine leaves behind
Bendamustine is not just another alkylating agent. Grade 3 to 4 lymphopenia has been reported in 62 to 92 percent of patients on it, with deeper lymphocyte depletion and slower recovery than R-CHOP causes. A large population-based study of older patients with indolent non-Hodgkin lymphoma found roughly a fourfold increase in CMV infection risk associated with bendamustine exposure. That gap between viral suppression and immune recovery is precisely what valganciclovir maintenance has to cover.
The recovery kinetics explain why timing gets difficult:
| Immune parameter | Typical course after bendamustine |
|---|---|
| Absolute lymphocyte count | Recovers in about 7 to 9 months |
| CD4+ T-cell count | May need 24 months or longer, further delayed by rituximab |
| CD4+ T-cell count despite normalized lymphocytes | About one quarter of patients remain CD4+ lymphopenic |
| Humoral immunity | Rituximab adds sustained B-cell depletion and hypogammaglobulinemia |
The last row is the one that matters at the bedside. A normalized absolute lymphocyte count does not mean cellular immunity is back, so lymphocyte counts are the wrong thing to watch. CD4+ T-cell counts track immune reconstitution better, and they are what this team followed.
Rituximab adds a separate hit. In one case series of non-transplant hematologic malignancies, 7 of 8 lymphoma patients who developed CMV infection had received rituximab-containing chemotherapy. In another comparison, CMV retinitis occurred in 5 of 138 patients given rituximab plus fludarabine-containing therapy, versus none of 141 patients on comparable regimens without rituximab.
What 13 months of valganciclovir maintenance looked like
The patient had stage IV splenic mantle cell lymphoma with bone marrow involvement, treated with eight cycles of R-CHOP followed by six cycles of bendamustine-rituximab plus ibrutinib. He also had glucose-6-phosphate dehydrogenase deficiency.
| Time point | Event |
|---|---|
| About 2 months after finishing bendamustine-rituximab | First episode of CMV colitis, confirmed by colonoscopic biopsy |
| 1 month later | Photophobia in the right eye |
| Following 2 months | Progressive peripheral visual field defects, right eye then left, with impaired color perception and right-eye floaters |
| Month 3 | Recurrent abdominal pain and worsening vision. Recurrent CMV colitis confirmed. CMV retinitis diagnosed |
| Induction | Intravenous ganciclovir 5 mg/kg every 12 hours for 24 days, then oral valganciclovir 450 mg twice daily |
| Referral, month 4 | Visual acuity 20/20 both eyes. Aqueous CMV PCR 27,600 IU/mL right eye. HSV PCR undetectable |
| Month 4 onward | Oral valganciclovir 900 mg daily plus repeated intravitreal ganciclovir 2 mg/0.04 mL |
| Month 6 | New occlusive retinal vasculitis in the left eye. Right-eye disease progressed despite combined therapy |
| Month 8 | Aqueous CMV PCR persistently positive at 3,707 IU/mL |
| Re-induction | Intravenous ganciclovir 5 mg/kg every 12 hours for 14 days plus weekly intravitreal ganciclovir |
| 2 weeks into re-induction | Blood CMV DNA fell from 129 to 40.1 IU/mL. Right-eye aqueous PCR undetectable |
| Month 10 | Left-eye aqueous CMV PCR positive at 1,036.2 IU/mL. Oral valganciclovir escalated from 900 mg daily to 900 mg twice daily |
| Month 12 | Left-eye aqueous PCR undetectable. CD4+ T cells recovered to 288 cells per microliter |
| Month 15 | Visual fields improved. Both aqueous and blood CMV PCR undetectable |
| Month 15, final visit | Oral valganciclovir discontinued. Stable at roughly 2 months of follow-up |
Read that table as a sequence of escalations. Induction, then maintenance, then intravitreal injections on top, then re-induction, then a dose escalation, and only then a stop date. Nothing about it was a straight line.
The recovery curve that made stopping possible
Antiviral therapy controlled the virus months before the immune system could hold it there. The gap between those two events is the whole reason extended valganciclovir maintenance was needed.
| Marker | At hospitalization | 1 month | 5 months | 7 months |
|---|---|---|---|---|
| CD4+ T cells (cells per microliter) | 109 | 199 | 288 | 352 |
| CD4/CD8 ratio | 0.085 | 0.11 | 0.21 | 0.24 |
| CD19+ B cells (percent) | 4.9 | 4.8 | 13.9 | 13.7 |
| IgG (mg/dL) | Below 320 | Not measured | 696 | 676 |
Three details there deserve attention. The CD4+ count tripled over seven months and still never reached the 410 to 884 reference band most laboratories quote, so a fixed numeric threshold would have flagged him as immunodeficient on the day treatment stopped.
Second, the IgG rise is not humoral recovery. He was on monthly intravenous immunoglobulin throughout, so those numbers measure the replacement product rather than his own antibody production. His IgA stayed low.
Third, B-cell reconstitution trailed T-cell recovery by months. Circulating CD19+ B cells were still under 5 percent in November 2025 and did not approach the normal range until March 2026.
What the published case pool says
A literature search across four databases through September 30 turned up 23 previously published patient-level cases of CMV retinitis following bendamustine-containing therapy, across 12 studies. The pattern is consistent enough to be useful.
| Feature of the published pool | Detail |
|---|---|
| Typical patient | Older adult with a hematologic malignancy, most often follicular lymphoma |
| Prior mantle cell lymphoma cases | 2 |
| Reported onset after bendamustine initiation | About 10 weeks to 36 months |
| Laterality | Bilateral ocular involvement predominated where laterality was reported |
| Treatment | Systemic antiviral therapy, often combined with intravitreal treatment |
| Reporting quality | Dosing and treatment duration inconsistently reported |
| Outcomes | Ranged from improvement or disease control to severe persistent visual loss |
This patient was substantially younger than the published pool, and he adds something the pool mostly lacks: longitudinal virological and immunological monitoring over more than a year. The practical gap the pool exposes is the one this case addresses: almost nobody has documented how the decision to stop valganciclovir maintenance was actually made, or what criteria were used.
The counterintuitive part: progression is not treatment failure
The right eye got worse while he was on oral therapy. Then it got worse again while he was on systemic treatment plus repeated intravitreal injections. That sequence invites a switch to foscarnet or cidofovir. It should not.
The re-induction response settles the question. Fourteen days of intravenous ganciclovir at 5 mg/kg every 12 hours drove blood CMV DNA from 129 to 40.1 IU/mL and turned the right-eye aqueous PCR from positive to undetectable. The virus was still ganciclovir-sensitive. What had gone wrong was local drug exposure and absent immune clearance, not resistance.
When CD4+ counts sit below roughly 50 to 100 cells per microliter, guidelines favor prolonging anti-CMV therapy over switching agents, provided adherence, intraocular exposure, and resistance have all been checked. Switching drugs in that setting trades a working drug for a more toxic one and leaves the real problem, which is absent immune control, untouched. Prolonging valganciclovir maintenance and adding intravitreal dosing is the response this framework supports.
There is a real caveat. UL97 and UL54 genotyping was never performed here, so resistance was not formally excluded. The conclusion rests entirely on how the virus responded to re-induction.
Immune recovery uveitis is the decoy
Later on, mild blurred vision with low-level CMV DNAemia of 111 and 81.5 IU/mL showed up in March and April 2026. Both episodes triggered aqueous sampling and empiric intravitreal ganciclovir, and both times the right-eye aqueous PCR was undetectable with no objective evidence of recurrent active retinitis.
This is immune recovery uveitis, and it is why the stopping decision is hard. Vitritis, retinal vasculitis, and mild symptoms during immune reconstitution look exactly like active infection. What separates them is that new retinal necrosis, extension of an active border, and renewed aqueous PCR positivity are all absent. Treat immune recovery uveitis as relapse and you extend antiviral therapy forever. Miss a real reactivation and the patient loses vision. Only aqueous PCR tells them apart.
Practical checklist for HIV-negative CMV retinitis
- Do not borrow the HIV discontinuation rule. It depends on antiretroviral-driven immune recovery these patients do not have.
- Monitor CD4+ T-cell counts, not absolute lymphocyte counts. About a quarter of patients stay CD4+ lymphopenic despite normalized lymphocytes.
- Treat progression during maintenance as an exposure problem first. Re-induce, add intravitreal therapy, and check adherence before assuming resistance.
- Genotype for UL97 and UL54 when the response is absent. It was not done here, and that is a real gap in the record.
- Require three conditions before stopping: inactive retinal lesions, undetectable CMV PCR in both aqueous humor and blood, and stable underlying hematologic disease.
- Expect valganciclovir maintenance to run for many months after chemotherapy ends, because CD4+ recovery rather than viral suppression sets the timeline.
- Watch the platelets. They fell from 223 x 10^9/L to 168 x 10^9/L during intravenous ganciclovir and recovered after completion without interrupting therapy.
- Expect renal function to hold. No dose reduction was needed here, but that is one case, not a rule.
- Suspect immune recovery uveitis when mild symptoms appear during CD4+ recovery, and confirm with aqueous PCR rather than treating on appearance.
Limitations
This is a single case report and cannot establish a discontinuation protocol, and it cannot define how long valganciclovir maintenance should run in general. Resistance genotyping was never performed, so the conclusion that progression reflected inadequate exposure rather than resistance is inferred from the response to re-induction. Follow-up after discontinuation was about two months, too short to exclude late relapse. Intravenous immunoglobulin confounds the immunoglobulin values, so humoral recovery cannot be read from them. The published pool is small and heterogeneous, with inconsistent reporting of dosing and duration. And the management described here happened where aqueous PCR, intravitreal injections, and multidisciplinary follow-up were all readily available, which is not true everywhere.
Bottom line
Valganciclovir maintenance after CMV retinitis in an HIV-negative patient ran 13 months in this case, for a plain reason: the antiviral controlled the virus months before the immune system could. Treatment stopped when three conditions converged, and not one of them was a CD4+ threshold. For patients on bendamustine, whose CD4+ recovery can take two years or longer, that distinction decides whether the eye survives. Valganciclovir maintenance is a holding action, and the immune system is what eventually takes over.
FAQ
How long does valganciclovir maintenance last after CMV retinitis
There is no fixed duration in HIV-negative patients. In this case oral valganciclovir continued for about 13 months, spanning induction, re-induction, repeated intravitreal injections, and dose escalation. Duration is individualized according to retinal inactivity, virological suppression, and stability of the underlying disease.
When can antiviral therapy be stopped
When three conditions hold at the same time: the retinal lesions are inactive on examination, CMV PCR is undetectable in both aqueous humor and blood, and the predisposing condition such as lymphoma remains in remission. A CD4+ T-cell count alone is not the stopping criterion outside HIV care.
Why is the HIV stopping rule not used here
The HIV rule requires a CD4+ count at or above 100 cells per microliter sustained for at least three months on antiretroviral therapy. Chemotherapy patients have no antiretroviral therapy to drive recovery, and CD4+ recovery after bendamustine can take 24 months or longer, so the rule would stop treatment too early.
Does progression during valganciclovir mean drug resistance
Not necessarily. In this case the right eye progressed on oral therapy and again on combined systemic and intravitreal treatment, yet 14 days of intravenous ganciclovir cleared aqueous CMV PCR. That pattern points to inadequate intraocular exposure and absent immune clearance rather than resistance.
Should the drug be switched when CMV retinitis progresses
Guidelines favor prolonging anti-CMV therapy over switching agents when CD4+ counts remain below about 50 to 100 cells per microliter, provided adherence, intraocular drug exposure, and resistance have been assessed. Switching replaces a working drug with a more toxic one without fixing absent immune control.
Why was resistance testing not done
UL97 and UL54 genotyping was not performed in this case, which is a genuine limitation of the report. The conclusion that the virus remained ganciclovir-sensitive rests on the observed virological response to re-induction rather than on molecular confirmation.
What is immune recovery uveitis
Immune recovery uveitis is intraocular inflammation that appears as the immune system rebuilds after CMV retinitis. It can produce vitritis, retinal vasculitis, and blurred vision that mimic active infection. The distinguishing test is aqueous humor PCR: negative in immune recovery uveitis and positive in true reactivation.
How fast does CD4 recovery happen after bendamustine
Absolute lymphocyte counts typically recover within about 7 to 9 months, while CD4+ T-cell recovery may need 24 months or longer and can be further delayed by rituximab. Roughly one quarter of patients remain CD4+ lymphopenic even after their lymphocyte count normalizes.
What is the role of intravitreal ganciclovir here
Intravitreal ganciclovir at 2 mg per 0.04 mL was used repeatedly alongside systemic therapy to raise intraocular drug concentrations when the right eye kept progressing. It supplements rather than replaces systemic treatment, and it was given according to disease activity rather than on a fixed schedule.
Does ganciclovir affect blood counts during treatment
It can. The platelet count fell from 223 x 10^9/L to 168 x 10^9/L during intravenous ganciclovir in this case and recovered after completion without interrupting therapy. Renal function remained preserved throughout and no dose reduction was required.
How common is CMV retinitis after bendamustine
It is rare. A literature search identified 23 previously published patient-level cases across 12 studies, mostly in older adults with hematologic malignancies and most often follicular lymphoma. Bendamustine exposure has been associated with roughly a fourfold increase in CMV infection risk in older patients with indolent lymphoma.
What is the visual outcome in published bendamustine cases
Outcomes ranged from improvement or disease control to severe persistent visual loss. In this case visual acuity remained preserved at 20/20, visual fields improved, and there was no evidence of active retinitis at the final follow-up roughly two months after antiviral therapy was discontinued.

Comments are closed